Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified

Circulation. 2014 Nov 18;130(21):1891-903; discussion 1903. doi: 10.1161/CIRCULATIONAHA.114.011319.
No abstract available

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / diagnosis*
  • Acute Coronary Syndrome / drug therapy*
  • Clopidogrel
  • Humans
  • Purinergic P2Y Receptor Antagonists / therapeutic use*
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / therapeutic use
  • Treatment Outcome

Substances

  • Purinergic P2Y Receptor Antagonists
  • Clopidogrel
  • Ticlopidine